Astrazeneca Pharma shares jump 3% after company gets CDSCO approval for import, sale of bladder cancer drug
AstraZeneca Pharma shares surged 3% today after the company received a key regulatory nod from India's Central Drugs Standard Control Organisation (CDSCO). The approval allows AstraZeneca to import and sell its cancer drug Durvalumab (branded as Imfinzi) in India for an additional use.
This new approval covers two dosage forms—120 mg/2.4 ml and 500 mg/10 ml—and expands Imfinzi's indication to treat adult patients with muscle invasive bladder cancer (MIBC). Specifically, the drug can now be used in combination with gemcitabine and cisplatin as a neoadjuvant (pre-surgery) treatment. After surgery (radical cystectomy), Imfinzi can continue as a standalone adjuvant (post-surgery) therapy.
The expanded label marks a significant milestone for AstraZeneca in India's oncology market, particularly in bladder cancer treatment. The company can now begin marketing Imfinzi for this new use, subject to any further clearances that may be needed.
Imfinzi is already approved globally for other cancer indications, including lung and biliary tract cancers. This latest CDSCO approval adds another layer to its growing clinical footprint in India.
AstraZeneca Pharma shares opened at ₹9,195.00 and touched a high of ₹9,650.50 during the day. The stock did not fall below its opening price, marking ₹9,195.00 as the low. Over the past year, the stock has seen a 52-week high of ₹10,691.00 and a low of ₹6,220.00.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
AstraZeneca PLC (AZN)'s Datroway Wins FDA Nod for Lung Cancer Breakthrough
We recently published 10 Most Undervalued Pharma Stocks To Buy Now. AstraZeneca PLC stands fifth on our list among the most undervalued stocks. AstraZeneca PLC (NASDAQ:AZN), a global biopharmaceutical company headquartered in Cambridge, UK, operates in over 130 countries with more than 80,000 employees. Formed in 1999 through the merger of Astra AB and Zeneca Group, the company is a leader in oncology, rare diseases, and biopharmaceuticals, with R&D hubs in Cambridge (UK), Gothenburg (Sweden), and Gaithersburg (US). A major recent milestone for the company is the U.S. FDA approval of Datroway (datopotamab deruxtecan) for patients with EGFR-mutated, previously treated non-small cell lung cancer (NSCLC). Datroway is the first TROP2-directed antibody-drug conjugate approved for this indication and offers improved progression-free and overall survival compared to chemotherapy, based on results from the Phase III TROPION-Lung01 trial. The drug was co-developed with Daiichi Sankyo, showcasing AstraZeneca PLC (NASDAQ:AZN)'s focus on collaborative innovation. This approval strengthens the company's extensive oncology portfolio, which includes Tagrisso, Imfinzi, and Enhertu, and supports its leadership in targeted cancer therapies. Beyond lung cancer, AZN is advancing treatments across other cancers. The SERENA-6 trial showed positive Phase III results for camizestrant, an oral SERD for HR-positive breast cancer, while the MATTERHORN trial reported promising data for Imfinzi in early-stage gastric and gastroesophageal junction cancers. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. AstraZeneca PLC (NASDAQ:AZN) continues to drive global oncology research, regularly presenting plenary data at leading medical conferences like ASCO, reflecting its position at the forefront of cancer innovation. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
2 hours ago
- Wall Street Journal
AstraZeneca Plans to Invest $50 Billion in U.S. by 2030
AstraZeneca AZN -0.60%decrease; red down pointing triangle said it plans to invest $50 billion in the U.S. by 2030, including a proposal for a new drug substance manufacturing center focused on weight-loss drugs. The U.K. biopharmaceutical giant said Monday the multi-billion dollar facility would produce drug substances for its weight-management and metabolic portfolio, including oral GLP-1s.
Bloomberg
2 hours ago
- Bloomberg
AstraZeneca Vows to Spend $50 Billion on US Manufacturing, Development
AstraZeneca Plc plans to invest $50 billion in the US before 2030, becoming the latest European pharma company to ratchet up spending in the country ahead of potential tariffs on imported medicines. The investment will go toward manufacturing as well as research and development, Astra said in a statement. It includes $4 billion for a new facility in Virginia that will make drugs for chronic diseases, Kevin Hassett, director of the US National Economic Council, said Monday at an event in Washington, DC.
